ATE246516T1 - Neue enzyme und prodrugs für adept - Google Patents

Neue enzyme und prodrugs für adept

Info

Publication number
ATE246516T1
ATE246516T1 AT95900827T AT95900827T ATE246516T1 AT E246516 T1 ATE246516 T1 AT E246516T1 AT 95900827 T AT95900827 T AT 95900827T AT 95900827 T AT95900827 T AT 95900827T AT E246516 T1 ATE246516 T1 AT E246516T1
Authority
AT
Austria
Prior art keywords
adept
prodrugs
enzymes
new enzymes
nucleic acid
Prior art date
Application number
AT95900827T
Other languages
English (en)
Inventor
Gary Keith Smith
Todd Andrew Blumenkopf
Michael Cory
Original Assignee
Wellcome Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wellcome Found filed Critical Wellcome Found
Application granted granted Critical
Publication of ATE246516T1 publication Critical patent/ATE246516T1/de

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6891Pre-targeting systems involving an antibody for targeting specific cells
    • A61K47/6899Antibody-Directed Enzyme Prodrug Therapy [ADEPT]
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B82NANOTECHNOLOGY
    • B82YSPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/66Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid the modifying agent being a pre-targeting system involving a peptide or protein for targeting specific cells
    • A61K47/67Enzyme prodrug therapy, e.g. gene directed enzyme drug therapy [GDEPT] or VDEPT
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/48Hydrolases (3) acting on peptide bonds (3.4)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/96Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nanotechnology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Medical Informatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Medicinal Preparation (AREA)
AT95900827T 1993-11-12 1994-11-11 Neue enzyme und prodrugs für adept ATE246516T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB939323429A GB9323429D0 (en) 1993-11-12 1993-11-12 Therapy
PCT/GB1994/002483 WO1995013095A2 (en) 1993-11-12 1994-11-11 Therapy

Publications (1)

Publication Number Publication Date
ATE246516T1 true ATE246516T1 (de) 2003-08-15

Family

ID=10745113

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95900827T ATE246516T1 (de) 1993-11-12 1994-11-11 Neue enzyme und prodrugs für adept

Country Status (15)

Country Link
US (2) US6140100A (de)
EP (1) EP0728018B1 (de)
JP (1) JPH09507834A (de)
AT (1) ATE246516T1 (de)
AU (1) AU688412B2 (de)
CA (1) CA2176024A1 (de)
DE (1) DE69433015T2 (de)
DK (1) DK0728018T3 (de)
ES (1) ES2204935T3 (de)
GB (1) GB9323429D0 (de)
IL (1) IL111601A0 (de)
MY (1) MY114140A (de)
NZ (1) NZ276137A (de)
WO (1) WO1995013095A2 (de)
ZA (1) ZA948987B (de)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9323429D0 (en) * 1993-11-12 1994-01-05 Wellcome Found Therapy
GB2309033B (en) * 1994-12-23 1999-06-02 Zeneca Ltd Chemical compounds
RU2189251C2 (ru) * 1994-12-23 2002-09-20 Зенека Лимитед Химические соединения
HUP9900062A3 (en) * 1995-08-16 1999-11-29 Zeneca Ltd Chemical compounds
GB9703201D0 (en) * 1997-02-15 1997-04-02 Zeneca Ltd Chemical compounds
AU2205499A (en) * 1997-12-31 1999-07-19 Incyte Pharmaceuticals, Inc. Human regulatory proteins
EP1242588A2 (de) 1999-11-12 2002-09-25 Lexicon Genetics Incorporated Menschliche proteine, die homologie zu carboxypeptidase aufweisen und dafür kodierende polynucleinsäuren
AU2002216864A1 (en) * 2000-12-21 2002-07-01 Mcgill University Conjugates of antibodies and anticancer drugs
KR20090057477A (ko) 2001-09-14 2009-06-05 글락소 그룹 리미티드 호흡기 질환 치료용 펜에탄올아민 유도체
KR20120068769A (ko) 2002-07-15 2012-06-27 더 보드 오브 리전츠 오브 더 유니버시티 오브 텍사스 시스템 음이온성 인지질 및 아미노인지질에 결합하는 선택된 항체 및 치료하는데 있어서 이의 용도
US20110002978A1 (en) 2003-06-17 2011-01-06 Harrison Roger G Enzyme prodrug cancer therapy selectively targeted to tumor cells or tumor vasculature and methods of production and use thereof
WO2005076744A2 (en) * 2004-02-18 2005-08-25 Frutarom Ltd. Method for the preparation of peptide-oligonucleotide conjugates
PT1794294E (pt) * 2004-09-27 2011-10-13 Sanofi Aventis Deutschland Carboxipeptidase b recombinante
CN101103018A (zh) * 2004-11-16 2008-01-09 神经化学(国际)有限公司 治疗cns和淀粉样蛋白-相关疾病的化合物
CA2705152C (en) 2007-11-09 2016-10-11 Peregrine Pharmaceuticals, Inc. Anti-vegf antibody compositions and methods
EP2491788B1 (de) 2011-02-25 2015-12-23 Kraft Foods R & D, Inc. Lebensmittelprodukt mit einem formkörper
US9340504B2 (en) * 2013-11-21 2016-05-17 Purdue Pharma L.P. Pyridine and piperidine derivatives as novel sodium channel blockers
RU2668166C1 (ru) * 2013-12-17 2018-09-27 Стелла Фарма Корпорейшн Способ получения 2-фтор-4-бороно-l-фенилаланина и вещества-предшественника 2-фтор-4-бороно-l-фенилаланина
US9987241B2 (en) 2014-09-25 2018-06-05 The Board Of Regents Of The University Of Oklahoma Enzyme conjugate and prodrug cancer therapy
US11446365B2 (en) 2017-08-09 2022-09-20 The Board Of Regents Of The University Of Oklahoma Antimalarial enzyme conjugates, kits containing same, and methods of producing and using same
US20250127913A1 (en) * 2021-06-24 2025-04-24 Lycia Therapeutics, Inc. Bifunctional folate receptor binding compounds
EP4370157A1 (de) 2021-07-14 2024-05-22 Lycia Therapeutics, Inc. Verbindungen und konjugate zur bindung des aspr-zelloberflächenrezeptors

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8705477D0 (en) * 1987-03-09 1987-04-15 Carlton Med Prod Drug delivery systems
GB8809616D0 (en) * 1988-04-22 1988-05-25 Cancer Res Campaign Tech Further improvements relating to drug delivery systems
US5433955A (en) 1989-01-23 1995-07-18 Akzo N.V. Site specific in vivo activation of therapeutic drugs
JP3273608B2 (ja) * 1989-01-23 2002-04-08 アクゾ・エヌ・ヴエー 治療薬の部位特異的インビボ活性化
AU633867B2 (en) * 1989-02-02 1993-02-11 Eli Lilly And Company Delivery of cytotoxic agents
FI94362C (fi) * 1989-10-20 1995-08-25 Squibb Bristol Myers Co Oleellisesti puhdistettu sulfataasi, menetelmä sen valmistamiseksi ja sitä tuottava Streptomyces-kanta
GB9200415D0 (en) * 1992-01-09 1992-02-26 Bagshawe Kenneth D Inactivation of cytotoxic drugs
US6187579B1 (en) * 1993-10-28 2001-02-13 Carlsberg A/S Customized proteases
GB9323429D0 (en) * 1993-11-12 1994-01-05 Wellcome Found Therapy
US5985627A (en) * 1997-02-28 1999-11-16 Carlsberg Laboratory Modified carboxypeptidase

Also Published As

Publication number Publication date
MY114140A (en) 2002-08-30
WO1995013095A3 (en) 1995-07-13
WO1995013095A2 (en) 1995-05-18
DK0728018T3 (da) 2003-11-24
GB9323429D0 (en) 1994-01-05
CA2176024A1 (en) 1995-05-18
ES2204935T3 (es) 2004-05-01
DE69433015T2 (de) 2004-06-09
JPH09507834A (ja) 1997-08-12
AU688412B2 (en) 1998-03-12
AU8148894A (en) 1995-05-29
ZA948987B (en) 1996-05-13
DE69433015D1 (de) 2003-09-11
NZ276137A (en) 1998-04-27
EP0728018B1 (de) 2003-08-06
IL111601A0 (en) 1995-01-24
EP0728018A1 (de) 1996-08-28
US6140100A (en) 2000-10-31
US6319702B1 (en) 2001-11-20

Similar Documents

Publication Publication Date Title
ATE246516T1 (de) Neue enzyme und prodrugs für adept
AU9737398A (en) Alpha-amylase mutants
DE69521331D1 (de) Nukleinsäure-einbringungssystem
ZA9711146B (en) Novel genes coding for amino acid deacetylase with specificity for N-acetyl-L-phosphinotricin, their isolation and use.
ATE321866T1 (de) Mutierte 5-enolpyruvylshikimat-3-phosphat synthase, für dieses protein kodierendes gen und dieses gen enthaltende transformierte pflanzen
HUT73962A (en) New bacillus thuringiensis strains and their insecticidal proteins
AU7327596A (en) Preparation of phosphorothioate oligomers
DE69231745D1 (de) Gensequenzen kodierend für Flavonoid-Stoffwechselwegenzyme und deren Verwendung
DE69738942D1 (de) Genetische sequenzen, welche für enzyme des flavonoid-stoffwechselweges kodieren und deren anwendungen
HUP9801638A2 (hu) Kevésbé adszorbeálódó és jobban hidrolizáló proteáz K variánsok
AU1430097A (en) Synthesis of methoxy nucleosides and enzymatic nucleic acid molecules
MX9800719A (es) Proteinas de transporte y sus usos.
AU4710393A (en) Production of phytate degrading enzymes in (trichoderma)
HUP9800765A2 (hu) Kevésbé adszorbeálódó és fokozottan hidrolizáló szubtilizin Carlsberg variánsok
AU2827895A (en) Purified polyporus laccases and nucleic acids encoding same
DE69928121D1 (de) Verwendungen von sulfatierten fuko-oligosacchariden zum pflanzenschutz
BG101892A (en) Sugar-modified cytostatics
HUP9800767A2 (hu) Kevésbé adszorbeálódó és jobban hidrolizáló szubtilizin DY variánsok
MX9703475A (es) D-pantolactona hidrolasa y gen que codifica para la misma.
MX9806041A (es) Proteina purificada sr-p70.
ZA982009B (en) Isolated nucleic acid molecules encoding SSX family members and uses thereof.
DE69631899D1 (de) Xylanasen, für diese kodierende gene und anwendungen derselben
GB9724627D0 (en) Gram positive microorganism formate pathway
ES2164545A1 (es) Enzimas con actividad beta-(1,6)-endoglucanasa.
AU7416100A (en) Dihydroorotase extracted from plants

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0728018

Country of ref document: EP

REN Ceased due to non-payment of the annual fee